2016 IMPAACT Annual Meeting Treatment Scientific Committee Presentations

Treatment Scientific Committee

Tuesday, June 14, 2016


Welcome/Overview of Treatment Scientific Agenda


Elaine Abrams and Ted Ruel

Early Infant Treatment


The Present and Future of Early Infant Treatment (Contact IMPAACT Operations Center)


Martina Penazzato

Nevirapine


Pharmacokinetics of Nevirapine for Prophylaxis in Premature/Low Birth Weight Infants in IMPAACT P1106 (Contact IMPAACT Operations Center)


Adrie Bekker


Modelled Treatment Dosing and Preliminary Pharmacokinetic and Safety Data from IMPAACT P1115 and BHP-074


Brookie Best


Nevirapine Dosing in High Risk Thai Infants (PHPT-5) (Contact IMPAACT Operations Center)


Tim R. Cressey

Raltegravir


Neonatal Population Pharmacokinetic Data from IMPAACT P1097, P1110, and P1066 (Contact IMPAACT Operations Center)


Diana Clarke


Pharmacokinetics and Safety Data from IMPAACT P1110 Cohort 2, Infants Receiving Daily Dosing (Contact IMPAACT Operations Center)


Diana Clarke

Dolutegravir


Pregnancy/Washout Pharmacokinetic Data and Congenital Anomalies from IMPAACT P1026s (Contact IMPAACT Operations Center)


Mark Mirochnick


Dosing in IMPAACT P1093 Cohort III, Granules Among Children 2 to 6 years of age (Contact IMPAACT Operations Center)


Ted Ruel

Upcoming IMPAACT Treatment Studies


IMPAACT 2006


Paul Palumbo


New Lopinavir/Ritonavir Formulation (Contact IMPAACT Operations Center)


Marc Lallemant


IMPAACT 2010


Judy Currier


Discussion, Conclusions, and Next Steps


Elaine Abrams and Ted Ruel